These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37673214)

  • 1. Revision of fluoroquinolone breakpoints used for interpretation of antimicrobial susceptibility testing of canine bacterial isolates.
    Papich MG; Gunnett LA; Lubbers BV
    Am J Vet Res; 2023 Nov; 84(11):. PubMed ID: 37673214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial resistance trends among canine Escherichia coli isolated at a New York veterinary diagnostic laboratory between 2007 and 2020.
    Osman M; Albarracin B; Altier C; Gröhn YT; Cazer C
    Prev Vet Med; 2022 Nov; 208():105767. PubMed ID: 36181749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
    Lazzerini G; Lavey SC; Fox BC; Munson E
    Clin Med Res; 2022 Jun; 20(2):81-88. PubMed ID: 35086853
    [No Abstract]   [Full Text] [Related]  

  • 4. Cephalexin susceptibility breakpoint for veterinary isolates: Clinical Laboratory Standards Institute revision.
    Papich MG; Lindeman C
    J Vet Diagn Invest; 2018 Jan; 30(1):113-120. PubMed ID: 29145786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa susceptibility, antibiogram and clinical interpretation, and antimicrobial prescribing behaviors for dogs with otitis in the Midwestern United States.
    KuKanich KS; Bagladi-Swanson M; KuKanich B
    J Vet Pharmacol Ther; 2022 Sep; 45(5):440-449. PubMed ID: 35698441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Setting Antimicrobial Susceptibility Testing Breakpoints: A Primer for Pediatric Infectious Diseases Specialists on the Clinical and Laboratory Standards Institute Approach.
    Pierce VM; Mathers AJ
    J Pediatric Infect Dis Soc; 2022 Feb; 11(2):73-80. PubMed ID: 34888640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats.
    Boothe DM; Boeckh A; Simpson RB; Dubose K
    J Vet Intern Med; 2006; 20(6):1297-306. PubMed ID: 17186841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from the Survey of Antibiotic Resistance (SOAR) 2016-17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Bratus E; Yuvko O; Pertseva T; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i100-i111. PubMed ID: 32337596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute.
    Satlin MJ; Nicolau DP; Humphries RM; Kuti JL; Campeau SA; Lewis Ii JS; Weinstein MP; Jorgensen JH
    Clin Infect Dis; 2020 Mar; 70(6):1240-1246. PubMed ID: 31504338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
    Gupta V; Yu KC; Pogue JM; Watts JA; Clancy CJ
    Microbiol Spectr; 2022 Jun; 10(3):e0115822. PubMed ID: 35638777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.
    Van TT; Minejima E; Chiu CA; Butler-Wu SM
    J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31043468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales.
    Tamma PD; Harris PNA; Mathers AJ; Wenzler E; Humphries RM
    Clin Infect Dis; 2023 Nov; 77(11):1585-1590. PubMed ID: 36001445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin.
    Gebru E; Choi MJ; Lee SJ; Damte D; Park SC
    J Med Microbiol; 2011 Oct; 60(Pt 10):1512-1522. PubMed ID: 21596912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Tunger A; Sancak B; Bıçakçıgil A; Altun B; Aktas Z; Kayacan C; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i88-i99. PubMed ID: 32337598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial Susceptibility Monitoring of Bacterial Pathogens Isolated from Urinary Tract Infections in Dogs and Cats Across Europe: ComPath Results.
    Moyaert H; Morrissey I; de Jong A; El Garch F; Klein U; Ludwig C; Thiry J; Youala M
    Microb Drug Resist; 2017 Apr; 23(3):391-403. PubMed ID: 28384093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Anwar S; Nizamuddin S; Malik N; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i76-i87. PubMed ID: 32337594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia.
    Torumkuney D; Mayanskiy N; Edelstein M; Sidorenko S; Kozhevin R; Morrissey I
    J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v14-v21. PubMed ID: 29659881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from the Survey of Antibiotic Resistance (SOAR) 2015-18 in Tunisia, Kenya and Morocco: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Hammami A; Mezghani Maalej S; Ayed NB; Revathi G; Zerouali K; Elmdaghri N; Gachii AK; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i2-i18. PubMed ID: 32337595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial testing of selected fluoroquinolones against Pseudomonas aeruginosa isolated from canine otitis.
    McKay L; Rose CD; Matousek JL; Schmeitzel LS; Gibson NM; Gaskin JM
    J Am Anim Hosp Assoc; 2007; 43(6):307-12. PubMed ID: 17975212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility monitoring of bacterial pathogens isolated from respiratory tract infections in dogs and cats across Europe: ComPath results.
    Morrissey I; Moyaert H; de Jong A; El Garch F; Klein U; Ludwig C; Thiry J; Youala M
    Vet Microbiol; 2016 Aug; 191():44-51. PubMed ID: 27374906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.